Ketazocine: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 01:21, 1 July 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChEMBL_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit		Revision as of 22:28, 9 August 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages taNext edit →
Line 1:		Line 1:
	{{drugbox		{{drugbox
		⚫	\| UNII_Ref = {{fdacite\|correct\|FDA}}
	\| Verifiedfields = changed
⚫	\| UNII_Ref = {{fdacite\|~~changed~~\|FDA}}
	\| UNII = 6IO4IG518S		\| UNII = 6IO4IG518S
	\| verifiedrevid = ~~400126983~~		\| verifiedrevid = 437151797
	\| IUPAC_name = (2''S'',6''R'',11''R'')-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2''H'')-one		\| IUPAC_name = (2''S'',6''R'',11''R'')-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2''H'')-one
	\| image = Ketazocine.svg		\| image = Ketazocine.svg
Line 18:		Line 17:
	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 2316328		\| ChemSpiderID = 2316328
	\| KEGG_Ref = {{keggcite\|~~changed~~\|kegg}}		\| KEGG_Ref = {{keggcite\|correct\|kegg}}
	\| KEGG = D04649		\| KEGG = D04649
	\| C = 18 \| H = 23 \| N = 1 \| O = 2		\| C = 18 \| H = 23 \| N = 1 \| O = 2

Revision as of 22:28, 9 August 2011

Pharmaceutical compound

Ketazocine
Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	?
Identifiers
IUPAC name (2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one
CAS Number	36292-69-0
PubChem CID	3054741
ChemSpider	2316328
UNII	6IO4IG518S
KEGG	D04649
CompTox Dashboard (EPA)	DTXSID10897529
Chemical and physical data
Formula	C₁₈H₂₃NO₂
Molar mass	285.38 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C2c1c(cc(O)cc1)3((2N(CC3)CC4CC4)C)C
InChI InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18+/m0/s1 Key:HQBZLVPZOGIAIQ-SDDDUWNISA-N
(verify)

Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the kappa opioid receptor.

Activation of this receptor causes a decrease in pain sensations and increased sleepiness but can also cause psychological symptoms such as feelings of unease, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)

Unlike other opioids, substances that only bind to the kappa receptor theoretically do not impair the normal drive to breathe.

References

Leander JD (1982 Sep). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. PMID 6128693. {{cite journal}}: Check date values in: |year= (help)CS1 maint: year (link)